Evidence map›Paper›PMID 41699065›Full record

ArticleScientific reports2026

Candidate biomarkers to identify mesothelioma patients at risk of developing venous thromboembolism post-surgery.

Adnan Shami-Shah, Shira Roth, Shad R Morton, Bogdan Budnik, William G Richards, Raphael Bueno, Rushdy Ahmad, David R Walt

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Adnan Shami-Shah *Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, USA.
Shira Roth *Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, USA.
Shad R Morton *Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, USA.
Bogdan BudnikWyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, USA.
William G RichardsDivision of Thoracic and Cardiac Surgery, Brigham and Women's Hospital, Boston, MA, USA.
Raphael BuenoDivision of Thoracic and Cardiac Surgery, Brigham and Women's Hospital, Boston, MA, USA.
Rushdy AhmadWyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, USA. rushdy.ahmad@wyss.harvard.edu.
David R WaltWyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, USA. dwalt@bwh.harvard.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pleural Mesothelioma (PM) is an aggressive cancer that attacks thousands of people every year. One of the common treatments is surgery to remove the tumor. Unfortunately, around 11% of patients die from blood clots post-surgery. Current predictive factors such as C-reactive protein, D-Dimer, and abnormal platelet count lack specificity. To date, no blood-based protein biomarkers have been identified to reliably predict PM patients at risk of developing Venous Thromboembolism (VTE) post-surgery. In this study, we present a set of host-response plasma protein candidate biomarkers that could predict patients at risk of developing VTE. We employed a quantitative mass spectrometry-based proteomics approach integrated with a multilayered, structured, and systematic evaluation of candidate biomarkers in a cohort of 18 patients, comprising six mesothelioma cases, six mesothelioma controls, and six lung cancer controls. This is the first step towards personalized treatment plans for PM patients undergoing surgery. This study’s findings can potentially guide subsequent, larger-scale investigations, highlighting the value of small-scale exploratory research.

Indexed as

Biomarkers, TumorLung NeoplasmsMesotheliomaPleural NeoplasmsPostoperative ComplicationsVenous ThromboembolismAgedBiomarkersFemaleHumansMaleMass SpectrometryMiddle AgedProteomicsRisk FactorsBiomarkersBiomarkers, TumorBiomarker discoveryMass spectrometryPleural mesotheliomaProteomicsVenous thromboembolism

Identifiers

PMID41699065
PMCPMC13000157

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.